Anixa Biosciences wins Australian patent for breast cancer vaccine through 2040
Bitget2026/09/21 16:06- Anixa Biosciences won its first Australian patent covering its breast cancer vaccine technology, extending exclusivity in Australia through 2040.
- The issued composition-of-matter patent covers vaccine adjuvants and formulations licensed from Cleveland Clinic.
- Anixa cited Phase 1 data showing the vaccine was safe, well tolerated, and triggered immune responses in more than 74% of participants.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Big short Burry increases short positions on Micron and Nebius, with the logic that "memory supply surge will put downward pressure on prices"
Michael Burry has dramatically increased his short positions on Micron, Palantir, and semiconductor ETFs, stating that the scale is “quite large.” His main reasoning is that Samsung, SK Hynix, and Micron squeezed their conventional DRAM production to meet AI-driven HBM demand, resulting in a shortage; however, with production capacity now ramping up, the Damocles sword of oversupply is hanging over the market. The inventory warning from Acer’s CEO has further convinced him that the memory cycle has already peaked.
Colorpak Indonesia announces extraordinary shareholder meeting
After doubling their stock prices this year, Valero Energy (VLO.US) and Marathon Petroleum (MPC.US) have been downgraded by Jefferies: Their valuations are now considered too high.
Jefferies downgraded refiners Valero Energy (VLO.US) and Marathon Petroleum (MPC.US) from "Buy" to "Hold," with target prices of $401 and $413, respectively.
Crypto prices
More
